Summary
Signal counts
Assets tracked: 4
Watchlist assets: 3
Registry stop assets: 1
Sponsor overview
Bristol-Myers Squibb
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00162266 | https://clinicaltrials.gov/study/NCT02828124 | https://clinicaltrials.gov/study/NCT01714739 | https://clinicaltrials.gov/study/NCT05613088
Assets
Linked programs
- Abatacept (BMS-188667): Watchlist Signal (2/5)
- BMS-986183: Registry Stop Signal (3/5)
- Lirilumab: Watchlist Signal (2/5)
- MORAb-202: Low Signal (1/5)